| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 31.06 | 1971 |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for Parkinson's Disease (PD) and related disorders affecting both the brain and peripheral systems. The company's lead candidate, IkT-148009, is a small molecule Abelson tyrosine kinase inhibitor targeting PD and its gastrointestinal complications, such as dysphagia and neurogenic constipation. Additionally, Inhibikase is advancing IkT-001Pro, a prodrug of the anti-cancer agent Imatinib, designed to reduce gastrointestinal side effects while treating blood and stomach cancers. With strategic collaborations with leading institutions like Johns Hopkins University and Arizona State University, Inhibikase leverages cutting-edge research to address unmet needs in neurology and oncology. Headquartered in Atlanta, Georgia, the company operates in the high-growth biotechnology sector, positioning itself as a potential disruptor in neurodegenerative disease treatment.
Inhibikase Therapeutics presents a high-risk, high-reward investment opportunity given its focus on Parkinson's Disease and related disorders—a market with significant unmet medical needs. The company's clinical-stage pipeline, particularly IkT-148009, holds promise, but its lack of revenue and negative earnings (-$27.5M net income in FY 2023) underscore its speculative nature. With $56.5M in cash and equivalents, Inhibikase has runway for near-term R&D, but further dilution or debt financing may be necessary. The stock's beta of 1.015 suggests market-correlated volatility, making it suitable only for risk-tolerant investors with a long-term horizon in biotech.
Inhibikase Therapeutics competes in the niche but rapidly evolving Parkinson's Disease therapeutics market, where its differentiation lies in targeting both central and peripheral symptoms. The company's Abelson tyrosine kinase inhibitor (IkT-148009) could offer a novel mechanism compared to traditional dopamine-focused therapies. However, it faces intense competition from larger biopharma firms with deeper pipelines and financial resources. Inhibikase's academic collaborations provide credibility but may limit commercialization speed versus in-house R&D at rivals. Its prodrug candidate (IkT-001Pro) enters a crowded oncology space dominated by generics, requiring clear efficacy advantages. The lack of marketed products puts Inhibikase at a disadvantage against commercial-stage peers, though early clinical success could attract partnership opportunities. Capital efficiency will be critical given the company's modest market cap ($131M) relative to trial costs.